Body Composition Monitor (BCM) is a portable device which uses bioimpedance spectroscopy to determine hydration status objectively in order to inform treatment decisions in patients on dialysis. The standard of care for assessing a dialysis patient’s hydration status is clinical judgement based on patient reported factors, which is unreliable, so this device is intended to provide an objective measure of fluid status and to improve clinical outcomes. Overhydration is a significant risk factor for a variety of morbidities and underhydration increases the risk of acute myocardial infarction. Patients on peritoneal dialysis (PD) tend to be at a greater risk of overhydration, which can lead to congestive heart failure.
The proposed study aims to compare patients treated using BCM to patients treated with clinical judgement alone. Patients' renal function will be measured at the beginning and the end of a 12 month double-blind randomised controlled trial.
Study status: The trial protcol is currently being finalised with input from expert nephrologists from six UK institutions.